Literature DB >> 9638122

Improving cost-effectiveness of hypertension management at a community health centre.

P R Edwards1, D W Lunt, G S Fehrsen, C J Lombard, K Steyn.   

Abstract

OBJECTIVES: To describe the pattern of prescribing for hypertension at a community health centre (CHC) and to evaluate the impact of introducing treatment guidelines and restricting availability of less cost-effective antihypertensive drugs on prescribing patterns, costs of drug treatment and blood pressure (BP) control.
DESIGN: Before/after intervention study.
SETTING: Medium-sized CHC in the Cape Flats area of Cape Town.
SUBJECTS: 1,084 hypertensive patients attending the CHC, who had at least two prescriptions for antihypertensive drugs during a 1-year period starting on 1 January 1992.
INTERVENTIONS: 1. Implementation of stepped-care guidelines for hypertension, specifying treatment with more cost-effective drugs and minimising drug treatment. 2. Reducing availability for routine prescribing by CHC doctors of 10 less cost-effective antihypertensive drugs or drug combinations. OUTCOME MEASURES: 1. Mean number of drugs prescribed per patient. 2. Proportion of prescriptions for: each major class of antihypertensive drug; restricted availability and freely prescribable drugs; and more and less cost-effective drugs. 3. Mean monthly cost of drugs prescribed per patient. 4. Mean blood pressure and proportion of BP readings controlled (< 160/95 mmHg) or uncontrolled (> or = 160/95 mmHg).
RESULTS: A mean of 1.7 active drugs was prescribed per patient per visit. The most frequently prescribed drugs were thiazide-like diuretics (44.8%), centrally acting agents (28.4%) and b-blockers (13.2%). Mean monthly drug costs per patient decreased significantly by R1.99 (24.2%) from R8.24 to R6.25 between the first and last prescription for each patient (exclusive of any reduction due to withdrawal of treatment). This was attributable to reduced prescribing of more expensive drugs withdrawn from routine use and a 51.1% increase in prescribing of the most cost-effective drugs. The overall annual cost-saving of the changes in prescribing for this CHC are estimated at R75 150. Blood pressure control did not change significantly.
CONCLUSION: The pattern of changes in prescribing and drug costs was consistent with a causal effect of the interventions. The study demonstrates the potential for improving cost-effectiveness of hypertension care in primary care in South Africa and the potential for research in this setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638122

Source DB:  PubMed          Journal:  S Afr Med J


  8 in total

Review 1.  Current studies in pharmacoeconomics.

Authors:  J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

2.  A comparison of two methods for measuring anti-hypertensive drug use: concordance of use with South African standard treatment guidelines.

Authors:  Thamizhanban Pillay; Anthony J Smith; Suzanne R Hill
Journal:  Bull World Health Organ       Date:  2009-06       Impact factor: 9.408

Review 3.  The state of health economic research in South Africa: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 4.  A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa.

Authors:  Andre Pascal Kengne; Lucas M Ntyintyane; Bongani M Mayosi
Journal:  Cardiovasc J Afr       Date:  2011-09-07       Impact factor: 1.167

5.  The economic burden of treating uncomplicated hypertension in Sub-Saharan Africa: a systematic literature review.

Authors:  E Gnugesser; C Chwila; S Brenner; A Deckert; P Dambach; J I Steinert; T Bärnighausen; O Horstick; K Antia; V R Louis
Journal:  BMC Public Health       Date:  2022-08-08       Impact factor: 4.135

6.  The managed hypertensive: the costs of blood pressure control in a Nigerian town.

Authors:  Olayinka Stephen Ilesanmi; Olusimbo Kehinde Ige; Akindele Olupelumi Adebiyi
Journal:  Pan Afr Med J       Date:  2012-08-06

7.  Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base.

Authors:  Jo-Ann Mulligan; Damian Walker; Julia Fox-Rushby
Journal:  Cost Eff Resour Alloc       Date:  2006-04-03

Review 8.  A Systematic Review of Economic Evidence on Community Hypertension Interventions.

Authors:  Donglan Zhang; Guijing Wang; Heesoo Joo
Journal:  Am J Prev Med       Date:  2017-12       Impact factor: 5.043

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.